{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumors%2C+Advanced+Solid+Tumors&page=3", "query": { "condition": "Solid Tumors, Advanced Solid Tumors", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 3364, "total_pages": 337, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumors%2C+Advanced+Solid+Tumors&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Tumors%2C+Advanced+Solid+Tumors&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T02:17:06.218Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03493945", "title": "Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer", "Prostate Cancer", "Prostate Neoplasm", "Advanced Solid Tumor", "Solid Tumor", "Non-metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "M7824", "type": "BIOLOGICAL" }, { "name": "N-803", "type": "DRUG" }, { "name": "MVA-BN-Brachyury", "type": "BIOLOGICAL" }, { "name": "FPV-Brachyury", "type": "BIOLOGICAL" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Ibuprofen", "type": "DRUG" }, { "name": "Naproxen", "type": "DRUG" }, { "name": "Benadryl", "type": "OTHER" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone scan", "type": "DIAGNOSTIC_TEST" }, { "name": "CT chest, abdomen and pelvis", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 59, "start_date": "2018-05-01", "completion_date": "2024-10-08", "has_results": true, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-10-09T02:17:06.218Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03493945" }, { "nct_id": "NCT04165772", "title": "Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Adenocarcinoma", "Clinical Stage: Stage II (T3-4, N-)", "Stage III (Any T, N+)", "Solid Tumor", "Solid Tumor, Adult" ], "interventions": [ { "name": "TSR-042 or Dostarlimab", "type": "DRUG" }, { "name": "capecitabine or 5-FU", "type": "DRUG" }, { "name": "Intensity Modulated Radiation Therapy (IMRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 212, "start_date": "2019-12-11", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-09T02:17:06.218Z", "location_count": 10, "location_summary": "Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04165772" }, { "nct_id": "NCT00045201", "title": "Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm" ], "interventions": [ { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2002-06-13", "completion_date": "2027-08-13", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-09T02:17:06.218Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00045201" }, { "nct_id": "NCT02880371", "title": "A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ARRY-382", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2016-09-01", "completion_date": "2019-10-24", "has_results": true, "last_update_posted_date": "2022-06-16", "last_synced_at": "2026-10-09T02:17:06.218Z", "location_count": 30, "location_summary": "Los Angeles, California • Santa Monica, California • Aurora, Colorado + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02880371" }, { "nct_id": "NCT05355701", "title": "A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-Small-Cell Lung Cancer", "Thyroid Cancer", "Glioma", "Advanced Colorectal Cancer (Part 1)" ], "interventions": [ { "name": "PF-07799933", "type": "DRUG" }, { "name": "binimetinib", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "midazolam", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 103, "start_date": "2022-07-05", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-09T02:17:06.218Z", "location_count": 31, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05355701" }, { "nct_id": "NCT01140607", "title": "Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Malignant" ], "interventions": [ { "name": "Cabazitaxel (XRP6258)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 56, "start_date": "2010-05", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2015-07-21", "last_synced_at": "2026-10-09T02:17:06.218Z", "location_count": 14, "location_summary": "La Jolla, California • Loma Linda, California • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01140607" }, { "nct_id": "NCT00508807", "title": "RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoid Malignancies", "Solid Tumors" ], "interventions": [ { "name": "RTA 402", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2006-04", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2012-07-30", "last_synced_at": "2026-10-09T02:17:06.218Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00508807" }, { "nct_id": "NCT02410512", "title": "A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody", "type": "DRUG" }, { "name": "MOXR0916, a humanized agonist anti-OX40 monoclonal antibody", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 610, "start_date": "2015-04-24", "completion_date": "2019-11-22", "has_results": false, "last_update_posted_date": "2022-04-01", "last_synced_at": "2026-10-09T02:17:06.218Z", "location_count": 9, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02410512" }, { "nct_id": "NCT00955292", "title": "Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Lymphoma" ], "interventions": [ { "name": "Quarfloxin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cylene Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2007-07", "completion_date": "2008-12", "has_results": false, "last_update_posted_date": "2009-08-10", "last_synced_at": "2026-10-09T02:17:06.218Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • San Antonio, Texas", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00955292" }, { "nct_id": "NCT05597839", "title": "Study of DF9001 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "DF9001", "type": "DRUG" }, { "name": "KEYTRUDA® (pembrolizumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dragonfly Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2022-11-15", "completion_date": "2025-08-15", "has_results": false, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-10-09T02:17:06.218Z", "location_count": 17, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Irvine, California + 14 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05597839" } ] }